NICE recommends kidney cancer drug it previously rejected on cost grounds.
作者信息
Mayor Susan
出版信息
BMJ. 2009 Feb 9;338:b499. doi: 10.1136/bmj.b499.
DOI:10.1136/bmj.b499
PMID:19204038
Abstract
摘要
相似文献
1
NICE recommends kidney cancer drug it previously rejected on cost grounds.英国国家卫生与临床优化研究所（NICE）推荐了一种此前因其成本原因而被拒绝的肾癌药物。
BMJ. 2009 Feb 9;338:b499. doi: 10.1136/bmj.b499.
2
Watchdog set to reject four drugs for kidney cancer on the NHS.监督机构准备拒绝国民保健制度（NHS）为肾癌开出的四种药物。
BMJ. 2008 Aug 14;337:a1262. doi: 10.1136/bmj.a1262.
3
Welcome clinical leadership at NICE.欢迎英国国家卫生与临床优化研究所的临床领导力。
Lancet. 2008 Aug 23;372(9639):601. doi: 10.1016/S0140-6736(08)61249-0.
4
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.苹果酸舒尼替尼用于转移性肾细胞癌一线治疗的经济学评价
J Clin Oncol. 2008 Aug 20;26(24):3995-4000. doi: 10.1200/JCO.2007.13.2662.
5
How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.成本效益分析如何为加拿大肿瘤药物的报销决策提供信息？以舒尼替尼作为转移性肾细胞癌一线治疗为例。
Value Health. 2010 Sep-Oct;13(6):837-45. doi: 10.1111/j.1524-4733.2010.00738.x. Epub 2010 Jun 7.
6
Cost effectiveness of sunitinib.舒尼替尼的成本效益
J Clin Oncol. 2008 Dec 10;26(35):5829; author reply 5829-30. doi: 10.1200/JCO.2008.19.8101. Epub 2008 Nov 10.
7
We have a new treatment, but you can't afford it.我们有一种新的治疗方法，但你负担不起。
J Natl Compr Canc Netw. 2006 Sep;4(8):720-3. doi: 10.6004/jnccn.2006.0063.
8
NICE celebrates 10th anniversary amid renal cancer drug controversy.在肾癌药物争议中，英国国家卫生与临床优化研究所庆祝成立10周年。
BJU Int. 2009 Apr;103(8):ii-iii. doi: 10.1111/j.1464-410X.2009.08579.x.
9
The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?英国国立临床优化研究所转移性肾细胞癌治疗指南的应用：是福是祸？
BJU Int. 2010 Aug;106(4):453-7. doi: 10.1111/j.1464-410X.2010.09466.x. Epub 2010 Jun 22.
10
Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.舒尼替尼、索拉非尼、替西罗莫司或贝伐单抗治疗转移性肾细胞癌：卫生经济学评价综述
J Chemother. 2010 Apr;22(2):75-82. doi: 10.1179/joc.2010.22.2.75.
引用本文的文献
1
Economic burden of renal cell carcinoma: Part I--an updated review.肾细胞癌的经济负担：第一部分——更新综述。
Pharmacoeconomics. 2011 Apr;29(4):315-29. doi: 10.2165/11586100-000000000-00000.
Zotero 插件